DIRS.INFO The most relevant business & tech news

☆ We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.
▼ + stars: | 2022-12-29 | by ( Yeji Jesse Lee | Leah Rosenbaum | ) www.businessinsider.com time to read: +8 min

A Congressional investigation into Biogen's controversial Alzheimer's drug Aduhlem was just released. Aduhelm was developed by Cambridge, Massachusetts-based biotech company Biogen and Japanese pharmaceutical company Eisai. The duo is currently developing another Alzheimer's drug, called lecanemab, which is expected to receive approval from the FDA in January and has shown more promising data in clinical trials. Insider reviewed the 45-page investigation into Biogen's Alzheimer's drug. Here are three of the most shocking takeaways:Biogen gave Aduhelm a crazy price tag despite knowing it would become inaccessible to many patientsFrom the moment Biogen announced Aduhelm's $56,000 price tag, the company faced backlash.

Organizations: & $

☆ A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes.
▼ + stars: | 2022-12-15 | by ( Leah Rosenbaum | ) www.businessinsider.com time to read: +7 min

Guardant Health said that its blood test to screen for cancer caught 83% of colorectal cancer cases. On Thursday, Silicon Valley-based biotech Guardant Health announced that its blood-based cancer screening test correctly caught colorectal cancer cases in 83% of people who had the disease. The company already has several products on the market, including Guardant360CDx, an FDA-approved blood test to test cancer genomic markers that could help show what treatments the cancers are susceptible to. Colonoscopies are still the gold standard of colorectal cancer screening, despite involving sedation and hours of unpleasant physical preparation. And while colorectal cancer is the first cancer that is being studied for a blood-based screening, it certainly won't be the last.

☆ See the presentations that cutting-edge biotech companies have used to raise millions from top investors
▼ + stars: | 2022-09-22 | by ( Leah Rosenbaum | ) www.businessinsider.com time to read: +6 min

Funding for biotech companies soared in 2021 to nearly $47 billion — a record for the industry. Insider rounded up all the biotech pitch decks we've published, from those seeking early-stage funding to presentations for late-stage rounds, that have helped companies raise money from investors. Here's the 24-slide pitch deck the company used to raise $175 million from investors like Leaps by Bayer. Here is the 24-slide pitch deck the company used to raise $120 million and prepare for regulatory approval in Japan. In late-stage funding rounds, the investors might also be different or used to backing bigger companies.

Amira Barger, 35, is helping healthcare become a more diverse and inclusive industry. Amira Barger. Courtesy of Amira BargerGrowing up in a missionary family in Guam, Amira Barger knew she wanted to do something with her life that brought goodness into the world. "COVID made the field of pharma and healthcare really look introspectively at their programs and the way they do their work," she said. If there is one thing that Barger wished her clients knew, it is that DEI impacts everyone across the healthcare sector, no matter their race, disability, sexual orientation, or position in the C-suite.

Persons: Amira Barger, Barger, She's, COVID, — Leah Rosenbaum Organizations: Centers for Disease Control, Federal Emergency Management Agency, Pfizer, Kaiser Permanente, pharma Locations: Guam, Kaiser

Search resuls for: "Leah Rosenbaum"

4 mentions found